Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy

Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing... ORIGINAL ARTICLE Phase 2 Study of Sorafenib in Malignant Mesothelioma  Previously Treated with Platinum-Containing  Chemotherapy Sophie Papa, MRCP, PhD,*║ Sanjay Popat, FRCP, PhD,†‡ Riyaz Shah, FRCP, PhD,§ A. Toby Prevost, PhD,║ Rohit Lal, MRCP, PhD,* Blair McLennan, BAppSc,* Paul Cane, FRCPath,* Loic Lang-Lazdunski, MD,*║ Zaid Viney, MRCP, FRCR,* Joel T. Dunn, PhD,* Sally Barrington, FRCP, FRCR,*║ David Landau, MRCP,*║ and James Spicer, FRCP, PhD*║ of sorafenib compares favorably with that reported for other targeted Introduction: The incidence of mesothelioma is rising. First-line agents, and suggests moderate activity in this disease. cisplatin and pemetrexed confers a survival benefit, with a median progression-free survival (PFS) of 5.7 months. Sorafenib inhibits Key Words: Mesothelioma, Sorafenib. tyrosine kinases, including receptors for vascular endothelial growth (J Thorac Oncol. 2013;8: 783-787) factor, which are implicated in mesothelioma pathogenesis by pre- clinical and clinical data. Methods: Sorafenib, at 400 mg twice daily, was assessed in a sin- alignant mesothelioma is a disease of the mesothelial gle-arm multicenter phase 2 study, using Simon’s two-stage design. Msurfaces of pleural and peritoneal cavities. More than Eligible patients had received platinum combination chemotherapy 80% of cases are pleural, and there is an overwhelming rela- earlier. The primary endpoint was PFS at 6 months, with secondary tionship with exposure to asbestos. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy

Spicer, James
Journal of Thoracic Oncology , Volume 8 (6) – Jun 1, 2013
Download PDF
5 pages

Loading next page...
 
/lp/wolters-kluwer-health/phase-2-study-of-sorafenib-in-malignant-mesothelioma-previously-WB7Lr1l8Yw

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2013 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e31828c2b26
pmid
23571475
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Phase 2 Study of Sorafenib in Malignant Mesothelioma  Previously Treated with Platinum-Containing  Chemotherapy Sophie Papa, MRCP, PhD,*║ Sanjay Popat, FRCP, PhD,†‡ Riyaz Shah, FRCP, PhD,§ A. Toby Prevost, PhD,║ Rohit Lal, MRCP, PhD,* Blair McLennan, BAppSc,* Paul Cane, FRCPath,* Loic Lang-Lazdunski, MD,*║ Zaid Viney, MRCP, FRCR,* Joel T. Dunn, PhD,* Sally Barrington, FRCP, FRCR,*║ David Landau, MRCP,*║ and James Spicer, FRCP, PhD*║ of sorafenib compares favorably with that reported for other targeted Introduction: The incidence of mesothelioma is rising. First-line agents, and suggests moderate activity in this disease. cisplatin and pemetrexed confers a survival benefit, with a median progression-free survival (PFS) of 5.7 months. Sorafenib inhibits Key Words: Mesothelioma, Sorafenib. tyrosine kinases, including receptors for vascular endothelial growth (J Thorac Oncol. 2013;8: 783-787) factor, which are implicated in mesothelioma pathogenesis by pre- clinical and clinical data. Methods: Sorafenib, at 400 mg twice daily, was assessed in a sin- alignant mesothelioma is a disease of the mesothelial gle-arm multicenter phase 2 study, using Simon’s two-stage design. Msurfaces of pleural and peritoneal cavities. More than Eligible patients had received platinum combination chemotherapy 80% of cases are pleural, and there is an overwhelming rela- earlier. The primary endpoint was PFS at 6 months, with secondary tionship with exposure to asbestos.

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jun 1, 2013

References

  • Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province
    Wagner
  • The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
    Hodgson
  • Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
    Vogelzang